The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Hello Hmmm
It is all quite complex and confusing for me so I can't give you a summary. The best thing is to sign up for the free service for Simply Wall Street and access it that way. I put it here as though some might be interested in the prediction.
Some strange figures today from LSE with yesterday's close at 99.5 and today's price shown at 1708 hrs at 102 yet the change in price from yesterday is shown as plus 4.50p. Methinks that the intraday chart is incorrect and yesterday's close should have been shown as 104p with today's loss of 4.50p.
Do not believe all on this site. My purchase today at 11.33.55 at 109.75 p was a BUY not a sell and so there must be many others wrongly recorded. Most of the sells are small amounts and thus likely to be other private investors. Keep the faith and buy now at a good price.
Many CEOs stay for a shortish time, create havoc, move on before found out and leave the mess for their successors to sort out and repeat the process many times hopping from one company to another. Another feature, sometimes known as the Peter Principle, is that people are promoted to the level at which they are shown to be incompetent but no further.
Selling out to larger companies should be resisted as I see huge growth in AGL income/eventual profits over the next 5/10 years and doubt if growth in profits of a successful take over company would be at the same rate when diluted by other business profits. No doubt those looking for a quick buck would be tempted to sell as we have seen here.
I believe the price is dropping as income growth will be slow and investors think they can do better elsewhere in the short term. Big good news and FDA approval should strongly reverse this trend. A good buying opportunity.
AGL is more of a one-track pony whereas Biogen is producing many different medications. As such AGL has most of its eggs in one basket which makes it more open to competition to build a similar filter. However, if as seems likely, Parsortex is very successful, it will be the goose that lays the golden egg for both cancer sufferers and investors. Cash receipts to AGL will be years in building up.
I have suspected for some time that there is manipulation of the share price. Today and yesterday, when buys have outpaced sales by 3 to the price goes down. Apart from MMs can anyone suggest who may be behind this apparent departure from normal economic theory? late announcement of trades and after-hours trades do not assist. The total number of shares sold usually exceeds the listed buys and sales sometimes by a large margin so we are not seeing the full story. This is also compounded by the fact that the algorithm often wrongly defines buys and sales.